tirzepatide cortisol study for diabetes: on track to SURPASS current therapy VisualAbstract: Tirzepatide Superior to Semaglutide

This contrasts with some single-pathway therapies that may show diminishing returns over time due to physiological adaptation or disease progression

To be eligible for Mounjaro, you must have: a BMI (body mass index) of 30kg/m or over (obese) a BMI between 27 and 30kg/m (overweight), and a weight-related health condition such as high cholesterol, high blood pressure, pre-diabetes or heart problems a BMI of 27.5kg/m and a higher risk ethnic background (South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean) You should let your prescriber know about any health problems you have and any medications you take so they can check Mounjaro is suitable for you

The medication works through a mechanism that mimics naturally occurring incretin hormones

discard if particulate matter or discoloration observed The Most Common Side Effects Nausea Diarrhea Decreased appetite Vomiting Constipation Indigestion Stomach (abdominal) pain The most common adverse reactions reported in 5% of Mounjaro-treated patients in placebo-controlled trials were nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain

Shortened life expectancy, increased healthcare costs and cardiometabolic complications are some of the consequences of this complex disease